Devalued and distrusted : can the pharmaceutical industry restore its broken image? / John L. LaMattina, Ph.D.
Material type:
TextPublisher: Hoboken, New Jersey : John Wiley & Sons, Inc., [2013]Description: ix, 125 pages : illustrations ; 25 cmContent type: - text
- unmediated
- volume
- 9781118487471
- 338.4/76151 23
| Item type | Current library | Call number | Materials specified | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
Books
|
MYCC Library General stacks | 338.476151 LAM 2013 (Browse shelf(Opens below)) | Available | ||||
Reference
|
MYCC Library Reference | 338.476151 LAM 2013 REF (Browse shelf(Opens below)) | Not for loan |
Browsing MYCC Library shelves, Shelving location: General stacks Close shelf browser (Hides shelf browser)
|
|
|
|
|
|
|
||
| 338.1 WIS 2019 Eating tomorrow : agribusiness, family farmers, and the battle for the future of food / | 338.1731809595 SAR 2019 The Status of the Paddy and Rice Industry in Malaysia / | 338.4760979473 GIL 2018 Life after Google : the fall of big data and the rise of the blockchain economy / | 338.476151 LAM 2013 Devalued and distrusted : can the pharmaceutical industry restore its broken image? / | 338.47622338095 TAN 2010 The oil and gas service industry in Asia : a comparison of business strategies | 338.47670975 ROS 1992 Competitive manufacturing : new strategies for regional development / | 338.5 PER 2014 Microeconomics : theory and applications with calculus / |
Includes bibliographical references and index.
Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts .
"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Provided by publisher.
There are no comments on this title.